UCSF Benioff Children's Hospital Antimicrobial Susceptibility Gram-negatives Inpatient/ED

N/A-testing NOT APPLICABLE to organism. CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime, GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, MER-meropenem, P/T-piperacillin-tazobactam

Values are % of strains testing susceptible to listed antibiotic. Unless indicated, results are for all inpatient/ED locations and culture sites.

Susceptibilities are based on data from 2019-2021. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimate. 

Organism Total Isolates*

CZOL

%S

(95% CI)

CTRX

%S

(95% CI)

CTAZ

%S

(95% CI)

CFPM

%S

(95% CI)

GEN

%S

(95% CI)

TOB

%S

(95% CI)

T/S

%S

(95% CI)

CIP

%S

(95% CI)

P/T

%S

(95% CI)

MER

%S

(95% CI)

Enterobacter cloacae

83

N/A

N/A

N/A

89 (98)#

(80,94)

100

(96,100)

98

(93,100)

93

(87,97)

93

(87,97)

75

(66,84)

98

(93,100)

Escherichia coli

292

60**

(55,67)

86

(82,90)

91

(88,94)

91 (94)#

(88,94)

90

(87,94)

92

(88,95)

64

(59,70)

78

(74,83)

97

(95,99)

100

(98,100)

Klebsiella oxytoca

53

18**

(10,32)

88

(77,95)

98

(90,100)

96

(87,99)

96

(87,99)

96

(87,99)

90

(80,96)

94

(85,98)

86

(74,93)

100

(92,100)

Klebsiella pneumoniae

100

66**

(56,75)

90

(83,94)

91

(84,95)

93

(86,97)

93

(86,97)

96

(90,98)

76

(67,83)

82

(73,88)

95

(89,98)

100

(96,100)

Pseudomonas aeruginosa 100*** N/A N/A

89

(82,94)

93

(86,97)

N/A

96

(90,98)

N/A

88

(80,93)

90

(83,94)

94

(88,97)

Serratia marcescens

38

N/A

97

(87,100)

97

(87,100)

97 (97)#

(87,100)

97

(87,100)

97

(87,100)

100

(91,100)

94

(83,99)

97

(87,100)

100

(90,100)

*When fewer than 30 isolates are reported, % susceptible may not reflect robust estimate of population susceptibility

**Reporting of Cefazolin susceptibility for E. coli, Klebsiella spp and Proteus is based on breakpoints for complicated infections - see outpatient E. coli susceptibilities for reporting based on uncomplicated UTI breakpoints

***Pseudomonas aeruginosa isolates do not include isolates from patients with cystic fibrosis.

# Number in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose dependent to cefepime, for each organism. Susceptible-dose dependent isolates of Enterobacteriaceae are those with MIC 4 to 8 micrograms/mL for a cefepime dose of 50 mg/kg/dose iv q8h with maximum 2g/dose, as routinely recommended per BCH Pediatric Antimicrobial Dosing Guidelines, is anticipated to be active.